Coronavirus treatment drugs market

Coronavirus Treatment Drugs Market, by Drug Class (Corticosteroids, Anti-viral, Monoclonal Antibodies, Kinase Inhibitors, and Others), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Request Free Sample

Dec 2020
CMI4312
175 Pages
Excel & Pdf
Pharmaceutical

Summary

The coronavirus (COVID-19) is an infectious disease caused by the novel coronavirus. Those affected by COVID-19 are likely to experience mild to moderate respiratory illness and recover without requiring special treatment, but people in the age group of 50 years and above, and those and suffering from other health disorders such as hypertension, diabetes, and kidney failure are at a severe risk of infection and require specific treatment. Moreover, currently there is no medication for treating the coronavirus, and health physicians are suggesting corticosteroids, anti-viral therapies for individuals with severe symptoms.

The global coronavirus treatment drugs market is estimated to be valued at US$ 15,912 million in 2020 and is expected to exhibit a CAGR of 17.5 % during the forecast period (2020-2027).

Figure 1. Global Coronavirus Treatment Drugs Market Value (US$ Mn), 2016-2027

The increasing prevalence of COVID-19 is expected to propel growth of the global coronavirus treatment drug market during the forecast period. According to the World Health Organization’s report, manifestation of COVID-19 has resulted in more than 60.9 million infected individuals worldwide as of 27th November 2020.

Furthermore, key companies are focused on research and development of treatments which is expected to propel growth of the global coronavirus treatment drugs market during the forecast period. For instance, in May 2020, the Washington University School of Medicine started the investigational clinical trial study on efficacy of the Duvelisib drug for the treatment of COVID-19. According to researchers from theWashington University School of Medicine, Duvelisib acts by PI3K inhibition, which could potentially reduce aberrant hyperactivtation of the innate immune system, preferentially polarize macrophages, reduce pulmonary inflammation, and limit viral persistence, and improve patients' health.

Coronavirus Treatment Drugs Market Report Coverage

Report Coverage	Details
Base Year:	2019	Market Size in 2020:	US$ 15,912 Mn
Historical Data for:	2016 to 2019	Forecast Period:	2020 to 2027
Forecast Period 2020 to 2027 CAGR:	17.5 %	2027 Value Projection:	US$ 49,204 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of the Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: Corticosteroids, Anti-viral, Monoclonal Antibodies, Kinase Inhibitors, Others. By Route of Administration: Oral, Intravenous. By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:	Serum Institute of India, Pfizer Inc., AstraZeneca plc., Bharat Biotech International Limited, Cadila Healthcare Limited, Johnson & Johnson, Moderna, GlaxoSmithKline plc., CanSino Biologics, Sinovac Biotech, Novavax, Inc., Glenmark Pharmaceuticals Limited, Dr. Reddy's Laboratories, and Merck & Co., Inc.
Growth Drivers:	Rising incidence of COVID-19 across the globe Increasing number of clinical trials by key players and academic institutes
Restraints & Challenges:	Increasing number of clinical trials by key players and academic institutes

Global Coronavirus Treatment Drugs Market – Impact of Coronavirus (COVID-19)

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. Currently, medication for treating COVID-19 is unavailable and several health organizations are recommending drugs which are prescribed for other health conditions but can be effective and safe for treating COVID-19.

For instance, in October 2020, the US National Library of Medicine stated that dexamethasone and remdesivir drugs can be used for the treatment of the patients suffering from severe and moderate symptoms of COVID-19. The individuals suffering from coronavirus infections are classified according to their severity of symptoms and health condition such as patients who are hospitalized but do not require oxygen; patients who are hospitalized and require oxygen, patients who are hospitalized and require non-invasive ventilation; and patients who are hospitalized and require invasive mechanical ventilation.

Figure 2. Global Coronavirus Treatment Drugs Market Share (%), By Region, 2020

North America is expected to hold dominant position in the global coronavirus treatment drugs market during the forecast period as key players are focusing on research and development of COVID-19 treatment. For instance, in June 2020, the Tufts Medical Center started investigational clinical trial study on drug Infliximab, a TNFα inhibitor therapy, which can be used in patients with severe COVID-19 symptoms and will prevent further clinical deterioration of patients with severe symptoms and reduce the need for advanced cardiorespiratory support. Currently the study is in the phase 2 of clinical trial.

Key Players

Major players operating in the global coronavirus treatment drugs market are Serum Institute of India, Pfizer Inc., AstraZeneca plc, Bharat Biotech International Limited, Cadila Healthcare Limited, Johnson & Johnson, Moderna, GlaxoSmithKline plc., CanSino Biologics, Sinovac Biotech, Novavax, Inc., Glenmark Pharmaceuticals Limited, Dr. Reddy's Laboratories, and Merck & Co., Inc.

Table of Content

*Browse 33 market data tables and 32 figures on " Coronavirus Treatment Drugs Market – Global forecast to 2027”.

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2020-2027)?

The global coronavirus treatment drugs market size is estimated to be valued at US$ 15,912 million in 2020 and is expected to exhibit a CAGR of 17.5 % between 2020 and 2027.

Which are the major drivers for growth of the global coronavirus treatment drugs market?

Rising incidence of COVID-19 across the globe and clinical trials by key players and academic institutes are driving growth of the global coronavirus treatment drugs market.

Which is the leading drug class type segment in the global coronavirus treatment drugs market?

Corticosteroids segment is estimated to hold major market share in the global coronavirus treatment drugs market during the forecast period owing to higher efficacy of corticosteroids in the treatment of COVID-19.

Which is the leading segment based on route of administration in the global coronavirus treatment drugs market?

The intravenous segment is estimated to hold major market share in the global coronavirus treatment drugs market during the forecast period owing to research and development of vaccines for the treatment of COVID-19.

Which region is estimated to generate the largest market share in 2020 in the global coronavirus treatment drugs market?

North America is estimated to generate largest revenue share in 2020 in the global coronavirus treatment drugs market.

Which are the key factors hampering growth of the market?

Lack of clinical knowledge about the novel coronavirus is hampering growth of the market.